Should I buy or sell Kiniksa Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks .

What is Kiniksa Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 1 year price targets for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $34.00. On average, they anticipate the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts .

How have KNSA shares performed in 2024?

Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA shares have increased by 13.2% and is now trading at $19.85. View the best growth stocks for 2024 here .

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024. View our KNSA earnings forecast .

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its earnings results on Tuesday, April, 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.11. The company had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative trailing twelve-month return on equity of 7.26%. The company's revenue was up 65.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) earnings per share.

What ETF holds Kiniksa Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.28% of its portfolio.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com . Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , Dicerna Pharmaceuticals (DRNA) , Vaxart (VXRT) and Advanced Micro Devices (AMD) .

When did Kiniksa Pharmaceuticals IPO?

Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hhlr Advisors LTD. (4.42%), Vanguard Group Inc. (4.20%), Rice Hall James & Associates LLC (0.88%), Altitude Crest Partners Inc. (0.56%), Peregrine Capital Management LLC (0.33%) and Essex Investment Management Co. LLC (0.24%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel. View institutional ownership trends .

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KNSA

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

→ Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad)

Free KNSA Stock Alerts

$19.83

+0.06 (+0.30%)

(As of 01:58 PM ET)

Compare

Today's Range: $19.73
▼
$19.98
50-Day Range: $16.88
▼
$20.46
52-Week Range: $13.37
▼
$22.09

Volume: 66,240 shs
Average Volume: 391,654 shs
Market Capitalization: $1.41 billion

P/E Ratio: 180.29
Dividend Yield: N/A
Price Target: $31.00

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 56.2% Upside
$31.00 Price Target
Short Interest: Bearish
5.51% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.83
Based on 3 Articles This Week
Insider Trading: Selling Shares
$709,929 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.10) to $0.39 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.03 out of 5 stars

Medical Sector

604th out of 918 stocks

Pharmaceutical Preparations Industry

283rd out of 429 stocks

3.5

Analyst's Opinion

Consensus Rating
Kiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kiniksa Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.
Read more about Kiniksa Pharmaceuticals' stock forecast and price target.

0.0

Short Interest

Percentage of Shares Shorted
5.51% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Kiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Kiniksa Pharmaceuticals has recently increased by 7.42%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kiniksa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kiniksa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KNSA.

2.7

News and Social Media Coverage

News Sentiment
Kiniksa Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,929.00 in company stock.
Percentage Held by Insiders
54.57% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Kiniksa Pharmaceuticals' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.10) to $0.39 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kiniksa Pharmaceuticals is 180.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 128.86.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kiniksa Pharmaceuticals is 180.47, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 113.81.
Price to Book Value per Share Ratio
Kiniksa Pharmaceuticals has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Kiniksa Pharmaceuticals' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Everybody laughed when he recommended Netflix

"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.

Click here to see how it could become the No. 1 investment of the next decade.

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

KNSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KNSA Stock News Headlines

May 16, 2024 | americanbankingnews.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Up 7.4% in April

May 10, 2024 | markets.businessinsider.com

Market Underestimates Kiniksa Pharmaceuticals’ Abiprubart Potential Despite Positive Industry Indicators

May 7, 2024 | globenewswire.com

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

May 4, 2024 | msn.com

Wells Fargo Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Overweight Recommendation

April 26, 2024 | finance.yahoo.com

Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report

April 25, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript

April 24, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects

April 24, 2024 | markets.businessinsider.com

Can Growing Adoption Of Arcalyst Drive KNSA Stock Up?

April 24, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

April 24, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript

April 24, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

April 24, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution

April 23, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call Presentation

April 23, 2024 | msn.com

Kiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlook

April 23, 2024 | markets.businessinsider.com

KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

April 23, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts

April 23, 2024 | globenewswire.com

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

April 20, 2024 | investing.com

Kiniksa Pharmaceuticals Ltd (KNSA)

April 16, 2024 | globenewswire.com

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

April 2, 2024 | globenewswire.com

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

March 7, 2024 | msn.com

5 Biotech Stocks With 26% Upside Potential or More

March 3, 2024 | investing.com

Earnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST sales

March 3, 2024 | wsj.com

Kiniksa Pharmaceuticals Ltd.

March 1, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

See More Headlines

Company Calendar

Last Earnings: 4/23/2024
Today: 5/20/2024
Next Earnings (Estimated): 7/23/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KNSA
CUSIP: N/A
CIK: 1730430
Web: www.kiniksa.com
Phone: (781) 431-9100
Fax: N/A
Employees: 297
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $31.00
High Stock Price Target: $34.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +56.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.11
Trailing P/E Ratio: 180.29
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $14.08 million
Net Margins: 2.78%
Pretax Margin: -7.15%
Return on Equity: -7.26%
Return on Assets: -6.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.21
Quick Ratio: 3.79

Sales & Book Value

Annual Sales: $270.26 million
Price / Sales: 5.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.23 per share
Price / Book: 3.18

Miscellaneous

Outstanding Shares: 70,940,000
Free Float: 32,228,000
Market Cap: $1.41 billion
Optionable: Optionable
Beta: 0.32

Key Executives

Mr. Sanj K. Patel (Age 55)
CEO & Chairman of the Board
Comp: $1.57M
Mr. Eben Tessari (Age 42)
Senior VP & COO
Comp: $733.29k
Dr. John F. Paolini FACC (Age 59)
M.D., Ph.D., Senior VP & Chief Medical Officer
Comp: $855.79k
Mr. Mark Ragosa C.F.A. (Age 50)
Senior VP & CFO
Mr. Michael R. Megna CPA (Age 53)
Chief Accounting Officer & Group VP of Finance
Mr. Chad Morin
Senior VP & Chief Compliance Officer
Ms. Madelyn Demsky Zeylikman (Age 50)
SVP, General Counsel & Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KNSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.
What is Kiniksa Pharmaceuticals' stock price target for 2024?: 4 Wall Street analysts have issued 1 year price targets for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $34.00. On average, they anticipate the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.
How have KNSA shares performed in 2024?: Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA shares have increased by 13.2% and is now trading at $19.85.
View the best growth stocks for 2024 here.
When is Kiniksa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024.
View our KNSA earnings forecast.
How were Kiniksa Pharmaceuticals' earnings last quarter?: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its earnings results on Tuesday, April, 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.11. The company had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative trailing twelve-month return on equity of 7.26%. The company's revenue was up 65.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) earnings per share.
What ETF holds Kiniksa Pharmaceuticals' stock?: Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.28% of its portfolio.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?: 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Kiniksa Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).
When did Kiniksa Pharmaceuticals IPO?: Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Kiniksa Pharmaceuticals' major shareholders?: Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hhlr Advisors LTD. (4.42%), Vanguard Group Inc. (4.20%), Rice Hall James & Associates LLC (0.88%), Altitude Crest Partners Inc. (0.56%), Peregrine Capital Management LLC (0.33%) and Essex Investment Management Co. LLC (0.24%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel.
View institutional ownership trends.
How do I buy shares of Kiniksa Pharmaceuticals?: Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNSA) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Book Value per Share Ratio

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

KNSA Stock Price History

KNSA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KNSA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™